smallpox vaccine; vaccinia vaccine (Dryvax, Arestvyr, Jynneos, Ankara-Bavarian Nordic vaccine, MVA-BN vaccine)

From Aaushi
Jump to navigation Jump to search
[1][2][3][4][5][6][7][8][9][10][11][12][13]

Introduction

Tradename: Dryvax. Only Jynneos FDA-approved[10]

Indications

Contraindications

Pharmacokinetics

Adverse effects

(see vaccinia)

Toxicity:

Mechanism of action

More general terms

References

  1. ↑ Prescriber's Letter 9(12):72 2002
  2. ↑ Action Report, Medical Board of California, 85:6 (April) 2003
  3. ↑ http://www.cdc.gov/smallpox
  4. ↑ 4.0 4.1 Frey SE et al Response to smallpox vaccine in persons immunized in the distant past. JAMA 289:3295, 2003 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12824212
  5. ↑ 5.0 5.1 Halsell JS et al Myopericarditis following smallpox vaccination among vaccinia- naive US military personnel. JAMA 289:3283, 2003 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12824210
  6. ↑ 6.0 6.1 Casey CG et al, Adverse events associated with smallpox vaccination in the United States, JAMA 2005; 294:2734 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16333009 Sejvar JJ et al, Neurologic adverse events associated with smallpox vaccination in the United States, 2002-2004 JAMA 2005; 294:2744 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16333010
  7. ↑ Casey C, Vellozzi C, Mootrey GT, Chapman LE, McCauley M, Roper MH, Damon I, Swerdlow DL. Surveillance guidelines for smallpox vaccine (vaccinia) adverse reactions. MMWR Recomm Rep. 2006 Feb 3;55(RR-1):1-16. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16456528 Corresponding NGC guideline withdrawn Dec 2011 http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5501a1.htm
  8. ↑ Physician's First Watch, March 14, 2013 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
    McNeil DG Wary of Attack With Smallpox, U.S. Buys Up a Costly Drug http://www.nytimes.com/2013/03/13/health/us-stockpiles-smallpox-drug-in-case-of-bioterror-attack.html
  9. ↑ Petersen BW, Harms TJ, Reynolds MG, Harrison LH Use of Vaccinia Virus Smallpox Vaccine in Laboratory and Health Care Personnel at Risk for Occupational Exposure to Orthopoxviruses - Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015 MMWR Weekly / March 18, 2016 / 65(10);257-262 http://www.cdc.gov/mmwr/volumes/65/wr/mm6510a2.htm
    Petersen BW, Damon IK, Pertowski CA et al Clinical guidance for smallpox vaccine use in a postevent vaccination program. MMWR Recomm Rep. 2015 Feb 20;64(RR-02):1-26. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25695372 Free Article
  10. ↑ 10.0 10.1 FDA News Release. Sept 24, 2019 FDA approves first live, non-replicating vaccine to prevent smallpox and monkeypox. https://www.fda.gov/news-events/press-announcements/fda-approves-first-live-non-replicating-vaccine-prevent-smallpox-and-monkeypox
  11. ↑ 11.0 11.1 Pittman PR, Hahn M, Lee HS et al. Phase 3 efficacy trial of modified vaccinia Ankara as a vaccine against smallpox. N Engl J Med 2019 Nov 14; 381:1897 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31722150 https://www.nejm.org/doi/10.1056/NEJMoa1817307
  12. ↑ 12.0 12.1 12.2 12.3 12.4 12.5 12.6 Deng L, Lopez LK, Glover C et al Short-term Adverse Events Following Immunization With Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) Vaccine for Mpox. JAMA. Published online May 5, 2023 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37145654 https://jamanetwork.com/journals/jama/fullarticle/2804849
  13. ↑ Centers for Disease Control & Prevention Monkeypox Vaccine Administration in the U.S. Data as of October 11 2022 https://www.cdc.gov/poxvirus/monkeypox/response/2022/vaccines_data.html
Retrieved from "https://aaushi.info/w/index.php?title=A5773&oldid=1154816"